CD19 and acute lymphoblastic leukemia: The initial anti-CD19 CAR-NK trial in 11 patients with relapsed or refractory CD19+ ALL-B demonstrated no adverse effects and a favorable clinical response, suggesting the potential importance of leveraging the antileukemic properties of NK cells [15, 138].